Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

318.78
Delayed Data
As of Jul 31
 +1.78 / +0.56%
Today’s Change
290.85
Today|||52-Week Range
480.18
-6.09%
Year-to-Date
This Latest Study Adds 1 More Piece to the Alzheimer's Puzzle
Aug 02 / MotleyFool.com
Tread Carefully in the Market
Jul 27 / TheStreet.com
Allergan is Cramer's Favorite Stock, Teva Deal Was 'Incredible'
Aug 01 / TheStreet.com
Cramer -- Intel's a Few Bucks Away From a Buy, but PayPal Is One Right Now
Jul 27 / TheStreet.com
The Blockbuster Potential of Biogen Inc's Pipeline
Aug 01 / MotleyFool.com
Cramer -- Be Careful Buying GrubHub, Biogen Is a Battleground
Jul 27 / TheStreet.com
Acorda 2Q Earnings & Revenues Top, Ampyra in Focus - Analyst Blog
Jul 31 / Zacks.com
Forget Biogen, Buy These Promising Biotech Stocks Instead - Analyst Blog
Jul 27 / Zacks.com
Price Isn't a Problem for Gilead Sciences
Jul 30 / TheStreet.com
3 Great Values to Buy on the Nasdaq - Analyst Blog
Jul 27 / Zacks.com
The Zacks Analyst Blog Highlights: Biogen, AbbVie, Regeneron, Amgen and XOMA - Press ...
Jul 30 / Zacks.com
Stock Market News for July 27, 2015 - Market News
Jul 27 / Zacks.com
Attention New Biotech Investors: Biogen Inc's Recent Weakness Is Your Opportunity
Jul 30 / MotleyFool.com
3 Signs That the Healthcare Stock Bubble Might Have Just Popped
Jul 27 / MotleyFool.com
Price Isn't a Problem for Gilead Sciences
Jul 30 / TheStreet.com
Biogen (BIIB) Stock Rebounding Following Bernstein Upgrade
Jul 27 / TheStreet.com
Troubled Stocks Go From Worst to First
Jul 29 / TheStreet.com
Biogen's Possible Takeout Targets and Other Key Questions After Blow-Up
Jul 27 / TheStreet.com
Sorry, No Fed Effect Today
Jul 29 / TheStreet.com
Biogen (BIIB) Marked As A Dead Cat Bounce Stock
Jul 27 / TheStreet.com
3 Stocks Pushing The Drugs Industry Lower
Jul 29 / TheStreet.com
Analysts Divided On Biogen Following $85 Selloff
Jul 27 / TheStreet.com
Biotech Stock Roundup: Biogen Down on Tecfidera Issues, Regeneron's Praluent Gets FDA...
Jul 29 / Zacks.com
Allergan sells generic drugs unit to Teva for $40bn
Jul 27 / FT.com
Stock Market News for July 29, 2015 - Market News
Jul 29 / Zacks.com
Biotech high flyers face gravity test
Jul 27 / FT.com
Make Sure You Don't Get Caught in a Breakdown
Jul 29 / TheStreet.com
Biogen's Terrible, Horrible, No Good, Very Bad Week
Jul 24 / MotleyFool.com
Jensen's Morning Musings
Jul 29 / TheStreet.com
Biogen (BIIB) Stock Plummets on Weak Guidance - Stocks in the News
Jul 24 / Zacks.com
Biogen Stock Remains Deeply Oversold
Jul 29 / TheStreet.com
Pandora hits right note for investors
Jul 24 / FT.com
Gilead Q2 Earnings: KAPOW! BAM! BOOM! (Yes, That Good)
Jul 28 / TheStreet.com
Week in Review, July 25
Jul 24 / FT.com
The Zacks Analyst Blog Highlights: Biogen, Ligand Pharmaceuticals, bluebird bio, Rege...
Jul 28 / Zacks.com
Biogen Tops Q2 Earnings, Cuts View on Tecfidera Issues - Analyst Blog
Jul 24 / Zacks.com
Watching Twitter for Moves at Teva and Biogen
Jul 28 / TheStreet.com
3 Alzheimer's Drugs Investors Should Be Watching
Jul 24 / MotleyFool.com
3 Big Biotech Buybacks That Investors Should Love
Jul 28 / MotleyFool.com
Biogen (BIIB) Beats on 2Q Earnings, Misses on Revenues - Tale of the Tape
Jul 24 / Zacks.com
'Mad Money' Lightning Round: Sell, Sell, Sell SanDisk
Jul 28 / TheStreet.com
Will Biogen (BIIB) Surprise in 2Q Despite Tecfidera Issues? - Analyst Blog
Jul 23 / Zacks.com
5 Things Biogen's Management Wants You to Know
Jul 27 / MotleyFool.com
Eli Lilly, Biogen Present Data at Alzheimer's Association - Analyst Blog
Jul 23 / Zacks.com
Cramer -- Twitter Has Short-Term Problems; Gilead's 'Problem' Is Too Much Cash
Jul 27 / TheStreet.com
Should You Buy Biogen (BIIB) Ahead of Earnings? - Tale of the Tape
Jul 23 / Zacks.com
Allergan signals appetite for new mega deal after $41bn disposal
Jul 27 / FT.com
Roche shrugs off copycat drugs threat
Jul 23 / FT.com
Is the U.S. Bull Market Starting to Lose Its Luster?
Jul 27 / TheStreet.com
Isis Pharmaceuticals Begins Huntington's Disease Study - Analyst Blog
Jul 22 / Zacks.com